Gene expression profiles of prolactinomas were compared with those of normal pituitary glands to identify differentially expressed genes (DEGs). Protein-protein interaction (PPI) analysis and protein complex prediction were performed to reveal the cross-talk between these genes and molecular mechanisms underlying the disease. Microarray data were downloaded from Gene Expression Omnibus. DEGs were screened using GEO2R and false discovery rate (FDR) < 0.05 was set as the cut-off. Protein-protein interaction (PPI) network was constructed with information from STRING and significant KEGG pathways were unveiled. Protein complexes were predicted using ClusterONE from Cytoscape and then validated in terms of pathways, protein domain, cellular localization and literatures. A total of 1712 genes (1911 probes) were found to be differentially expressed in prolactinoma. Interactions were identified among 121 protein products. Nineteen significant pathways (FDR< 0.05) were acquired and pathways in cancer was the top one. Pathways linked to myeloid leukemia and tryptophan metabolism were also enriched in the DEGs. Four protein complexes were predicted and then validated. They were associated with focal adhesion, cytoskeleton, metabolism of tryptophan, arginine and proline as well as aldehyde dehydrogenases. They might play important roles in the pathogenesis of prolactinoma. In present study, not only DEGs were provided, but also PPIs and protein complexes were discussed. These findings promoted the knowledge about prolactinoma and provided novel candidate targets for the therapy development of prolactinoma.
Prolactinoma is the most common type of pituitary tumor as it accounts for 60% of functional pituitary adenomas [1, 2] . It causes hyperprolactinemia and exerts pressure on surrounding tissues. Dopamine agonist can be used to inhibit prolactin secretion. Surgery is another option while medical therapy fails to reduce prolactin levels and tumor size. However, approximately 20% of prolactinomas may exhibit either dopamine agonist resistance or high recurrence rates after operation [3] . Therefore, a better understandin the pathogenesis of prolactinoma is necessary for development of improved therapies.
Many studies demonstrate that growth factors play an important role in the pathogenesis of prolactinoma. Santos-Silva et al. indicate that human epidermal growth factor receptor 2 (HER2) /ErbB2 receptor signaling plays a role in prolactinoma cell proliferation and thus can be targeted to treat this disease [4] . Estrogen can induce expression of many growth factors via estrogen receptor α. Lv et al. report that estrogen receptor α correlates with prolactin (PRL) levels and tumor volume, and may be an effective therapy target [5] . Cooper et al. further demonstrate that prolactinoma expression of specific ErbB receptors is associated with tumor invasion, symptoms, and response to dopamine agonists [6] .
Several transcription factors (TFs) are also revealed in prolactinoma. Tong et al. identify CCAAT-enhancer-binding protein δ (CEBPD) transcription factor as a critical gene that partially suppresses both PRL expression and lactotroph cell proliferation [7] . Palmieri et al. find that pituitary-specific transcription factor 1 (PIT1) upregulation by HMGA proteins has a role in pituitary tumorigenesis [8] . Expression of steroidogenic factor 1 and PIT1 can be used for classification of rat pituitary adenomas [9] .
Furthermore, Jiang et al. have already applied fiber-optic BeadArray approach combined with Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of differential gene expression in prolactinoma. This study has found that 27 up-regulated genes and 182 down-regulated genes were identified using array analysis. KEGG pathway analysis showed that P53 and GnRH signaling pathways might be involved in tumorigenesis of prolactinomas. Compared with the above study, we attached more importance to protein interactions and prediction of protein complexes involved in significant pathways, in addition to analysis of DEGs and pathways in prolactinomas. Specifically, in present study, microarray-based gene expression profiling was performed to identify differentially expressed genes (DEGs) between prolactinomas and normal pituitary glands. Protein-protein interactions (PPIs) and protein complexes were explored with bioinformatic tools to gain insights into the pathogenesis of prolactinoma.
Materials and methods
Microarray data. Microarray data set GSE36314 [10] was downloaded from Gene Expression Omnibus. It included 4 human prolactinoma samples and 3 normal pituitary gland samples. GPL8300 [HG_U95Av2] Affymetrix Human Genome U95 Version 2 Array was utilized to obtained gene expression profiles.
Screening of DEGs. DEGs were screened using GEO2R. GEO2R employed GEOquery of BioConductor and package limma of R to finish the statistical analysis [11] . Package limma (Linear Models for Microarray Analysis) was used to perform multiple-testing corrections on p-value and thus minimized false discovery rate (FDR) [12] . FDR< 0.05 was set as the cutoff. KEGG pathways enrichment analysis was performed for up-and down-regulated DEGs using database for annotation, visualization, and integrated discovery (DAVID) [13] . A pvalue < 0.05 was used as a strict threshold for the pathway enrichment analysis.
Construction of PPI network. PPI network was constructed with information from STRING [14] , which collects interaction information from genomic context, high-throughput experiments, coexpression and previous knowledge. Interactions with confidence > 0.4 were retained and then visualized using Cytoscape. KEGG significant pathways were marked and they might play roles in the development of prolactinoma. FDR< 0.05 was set as the criterion.
Prediction of protein complex. Protein complexes were predicted using ClusterONE (Clustering with Overlapping Neighborhood Expansion) from Cytoscape. ClusterONE adopted graph clustering to handle weighted graphs and thus revealed overlapping clusters [15] . The minimum size was set as 3, which meant that cluster with less than 3 genes would be ignored, and minimum density was set as "auto". The score given by STRING was considered as the weight (i.e. edge weight).
Validation of predicted protein complexes. Four methods could be used to validate the predicted protein complexes: KEGG pathway enrichment analysis; protein domain; cellular components enrichment analysis; Gene ontology (GO) term enrichment analysis. DAVID was used to carry out these analysis.
Results

DEGs.
A total of 1911 probes (corresponding to 1712 genes) were found to be differentially expressed according to the threshold (FDR< 0.05). Among these DEGs, top 10 upand down-regulated genes were listed in Table 1 . As shown in Table 2 , up-regulated DEGs were significantly enriched in 7 pathways. Of the 7 pathways, Huntington's disease, Parkinson's disease and oxidative phosphorylation pathways were most significant. Down-regulated DEGs were significantly enriched in 21 pathways. Of the 21 pathways, most significantly enriched pathways included colorectal cancer, pathways in cancer, neurotrophin signaling pathway, MAPK signaling pathway and cell adhesion molecules (CAMs) pathways.
PPI network of DEGs. A total of 1081 proteins were found in STRING (Figure 1 ). Interactions were identified among 121 proteins.
Enriched KEGG pathways in PPI network. A total of 19 KEGG pathways were obtained according to the threshold (FDR< 0.05) ( Table 3 ). The top term was "pathways in cancer" with 50 genes. Two pathways related to myeloid leukemia were also enriched. There's certain association between myeloid leukemia and pituitary prolactinoma according to a recent medical report [16] . Tryptophan metabolites, such as serotonin (5-HT) and kynerenines (KYNs), are strong and effective substances regulating mood and behavior. Hormone secreted by the pituitary gland can regulate the metabolism of tryptophan [17] . Meanwhile, tryptophan metabolic process can in turn regulate neurogenesis in the hypothalamic -pituitary -adrenal axis [18] . Therefore, it's not unexpected that this pathway was enriched in the DEGs.
Protein complexes in DEGs. A total of 4 protein complexes were revealed using ClusterONE from Cytoscape. Their PPI networks are shown in Figure 2 . Genes included in the enriched KEGG pathways were in red. Genes in complex 1 were involved in a range of important pathways, such as focal adhesion (hsa04510), ECM-receptor interaction (hsa04512), arrhythmogenic right ventricular cardiomyopathy (hsa05412), small cell lung cancer (hsa05222) and regulation of actin cytoskeleton (hsa04810) ( Table 4) . Complex 1 was mainly enriched outside the cell membrane. Complex 3 was implicated in tryptophan (hsa00380), arginine and proline metabolisms (hsa00330), as well as decomposition of limonene and pinene Table 4 ). Significant pathways revealed by DAVID from these protein complex 1 and 3 were consistent with those by ClusterONE. Besides, protein domain analysis and cellular component enrichment analysis further confirmed the truth of the protein complexes (Table 4) .
No significant KEGG pathway (FDR < 0.05) was enriched in protein complex 2. However, "SNARE interactions in vesicular transport (hsa04130)" was acquired if the criterion was broadened to p-value < 0.05 (Table 4) . SNARE is mainly involved in fusion between extracellular transport vesicle and cell Quality: quality of the cluster, calculated as percentage of heavy weight edge in the cluster accounting for all; p-value: the reliability of the cluster.
membrane or extracellular substance transport by lysosomals ( Figure 3 ). According to GO cellular component analysis, 75% of the proteins were located in cell membrane, confirming its roles in membrane fusion. Moreover, this kind of pathway was associated with diseases, such as pseudo hypoparathyroidism, cerebral dysgenesis and neuropathy. Therefore, this protein complex should exist in the DEGs. In protein complex 4, 75% proteins were located in organelles. Protein domain analysis and KEGG pathways were related to RNA recognition, post-transcriptional splicing and purine metabolism. This complex was also validated by Interpro, GO cellular component analysis and KEGG pathway analysis (FDR > 0.05, p-value < 0.05). It's observed in retinitis pigmentosa (hsa03040) ( Table 4) . Pigmentary degradation was reported in two male patients with pituitary tumors [19] . This information suggested the certainty of protein complex 4.
Discussion
A total of 1911 differentially expressed probes corresponding to 1712 DEGs were identified in prolactinomas compared to normal pituitary glands. PPI networks were constructed for 121 protein products of the DEGs and 19 significant KEGG pathways were revealed as well. Four protein complexes were predicted using ClusterONE and they were validated in terms of enriched pathways, protein domain, GO cellular component and literatures. Protein complex 1 was linked to focal adhesion, cytoskeleton, extracellular matrix interactions, as well as cardiac arrhythmias and lung cancer. Protein complex 3 was related to tryptophan, arginine and proline metabolic pathway.
As shown in Table 3 , a considerable part of pathways were associated with cancers. Given prolactinoma was also a type of pituitary tumor, it's not unexpected that these pathways were enriched in the DEGs. Moreover, it granted reliability to our study. Pathways related to metabolisms of tryptophan, arginine, proline and others were also significant. Pituitary gland is an important endocrine gland secreting nine hormones that regulate homeostasis. Obviously, abnormality in this gland will cause metabolic disorder. The study by Bergstrom et al. indicate a remarkable decrease of the amino acid metabolism in prolactinomas after bromocriptine treatment [20, 21] , which verified the disorder in metabolisms and supported our result in certain degree. As stated earlier, Tryptophan metabolites include 5-HT. 5-HT stimulation of GABAergic neurons and indirect modulation of prolactin release by 5-HT is considered of one of the mechanisms underlying the association of antidepressants with hyperprolactinaemia [22] . It indicated the metabolism of tryptophan might be a candidate target for prolactinoma treatment.
Besides, MAPK signaling pathway and ECM-receptor interaction were also enriched in the DEGs. Mitogen-activated protein kinase (MAPK) signal transduction pathway is involved in regulation of prolactin gene expression by estrogen [23] . Pei et al. report that MAPK cascade regulates pituitary tumor-transforming gene function, an oncogene acting as a transcriptional activator [24] .
To further describe the interactions between DEGs and their roles in the development of prolactinoma, protein complexes were predicted by ClusterONE and four complexes were revealed. Many integrins that mediates cell-cell and cell-extracellular matrix interactions were included in protein complex 1, and that was in accordance with enriched signal transduction pathways. Collagens were extracellular matrix proteins and they were also included in protein complex 1. Our results supported the idea that differential expression of extracellular matrix components, integrins and matrix metalloproteinase contributes to the control of pituitary hormone production and cell proliferation during tumorigenesis [25] . Similarly, the role of ECM receptor interactions pathway is revealed in the tumorigenesis and progression of Growthhormone-secreting pituitary adenomas [26] . Protein complex 3 was associated with amino acid metabolism, tryptophan, arginine and proline metabolisms, as well as decomposition of limonene and pinene, and that was also in line with enriched signaling pathways. It might explain increased secretion of PRL and other hormones. A number of aldehyde dehydrogenases (ALDH) genes were enriched in protein complex 3 as well. ALDH are a group of enzymes catalyzing the oxidation of acetaldehyde and transforming it into acetate [27] . Abnormal activity of ALDH is implicated in a variety of cancers such as lung, colorectal and breast cancer [28] [29] [30] .This study indicated ALDH is involved in prolactinoma as well, and might be a possible biomarker for this disease. Besides, SNARE interactions in vesicular transport was "partially" enriched in protein complex 2, which was also associated with hormone secretion [31] . Garcia et al. propose a SNARE-targeted strategy to inhibit secretion of growth hormone [32] . It might be useful for treatment of prolactinoma. Garcia et al. find that vesicle-associated membrane protein 2&3 (VAMP2&3), SNAP-23 and syntaxin1 are the predominant SNARE-proteins in somatotroph adenomas. Therefore, VAMP-associated protein A (VAPA), VAMP7 and VAMP8 were worthy of further investigations to verify their expression profiles in prolactinoma. Protein complex 4 was linked to RNA recognition and splicing, which contributed to the disorder during development of prolactinoma.
When summarizing, our study supported previous findings and provided new insights into the molecular mechanisms, especially hormone secretion-related genes like VAPA, VAMP7&8. This knowledge also provided possible candidate targets such as metabolism of tryptophan and ALDH activity. That would benefit future therapy development for prolactinoma.
